When can a woman have repeat progestogen-only injectables-depot medroxyprogesterone acetate or norethisterone enantate?

Contraception

Volumn 80, Issue 4, 2009, Pages 391-408

  Paulen, Melissa E ^a   Curtis, Kathryn M ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Depot medroxyprogesterone acetate (DMPA); Norethisterone enantate (NET EN); Progestogen only contraception; Reinjection; Systematic review

Indexed keywords

GESTAGEN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE;

FEMALE; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL LITERATURE; MEDLINE; OVULATION; PREGNANCY RATE; PUBLICATION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW;

FEMALE; FERTILITY; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; NORETHINDRONE; OVULATION; PREGNANCY;

EID: 69949137182     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.03.023     Document Type: Review

References (31)

1. Trussell J. Contraceptive failure in the United States. Contraception 70 (2004) 89-96
2. World Health Organization. Selected practice recommendations for contraceptive use. 2nd ed. (2005), World Health Organization, Geneva
3. Baumgartner J.N., Morroni C., Mlobeli R.D., et al. Timeliness of contraceptive reinjections in South Africa and its relation to unintentional discontinuation. Int Fam Plan Perspect 33 (2007) 66-74
4. Mohllajee A.P., Curtis K.M., Flanagan R.G., Rinehart W., Gaffield M.L., and Peterson H.B. Keeping up with evidence a new system for WHO's evidence-based family planning guidance. Am J Prev Med 28 (2005) 483-490
5. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20 (2001) 21-35
6. Steiner M.J., Kwok C., Stanback J., et al. Injectable contraception: what should the longest interval be for reinjections?. Contraception 77 (2008) 410-414
7. Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo Provera: up-dated data analysis. J Biosoc Sci 16 (1984) 23-34
8. Jain J., Dutton C., Nicosia A., Wajszczuk C., Bode F.R., and Mishell Jr. D.R. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 70 (2004) 11-18
9. Toh Y.C., Jain J., Rahnny M.H., Bode F.R., and Ross D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin Ther 26 (2004) 1845-1854
10. Garza-Flores J., Cardenas S., Rodriguez V., Cravioto M.C., Diaz-Sanchez V., and Perez-Palacios G. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study. Contraception 31 (1985) 361-366
11. Bassol S., Garza-Flores J., Cravioto M.C., et al. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses. Fert Steril 42 (1984) 216-222
12. Lan P.T., Aedo A.R., Landgren B.M., Johannisson E., and Diczfalusy E. Return of ovulation following a single injection of depo-medroxyprogesterone acetate: a pharmacokinetic and pharmacodynamic study. Contraception 29 (1984) 1-18
13. Fotherby K., Koetsawang S., and Mathrubutham M. Pharmacokinetic study of different doses of Depo Provera. Contraception 22 (1980) 527-536
14. Fotherby K., Saxena B.N., Shrimanker K., et al. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate. Fert Steril 34 (1980) 131-139
15. Saxena B.N., Dusitsin N., Tankeyoon M., and Chaudhury R.R. Return of ovulation after the cessation of depot-medroxyprogesterone acetate treatment in Thai women. J Med Assn Thailand 63 (1980) 66-69
16. Ortiz A., Hirol M., Stanczyk F.Z., Goebelsmann U., and Mishell D.R. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 44 (1977) 32-38
17. Banerjee S.K., et al., ICMR (Indian Council of Medical Research) Task Force on Hormonal Contraception. Return of fertility following discontinuation of an injectable contraceptive-norethisterone oenanthate (NET EN) 200 mg dose. Contraception 34 (1986) 573-582
18. Banerjee S.K., Baweja R., Bhatt R.V., et al. Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200 mg) injectable contraceptive given every two or three monthly. Indian Council of Medical Research Task Force on Hormonal Contraception. Contraception 30 (1984) 561-574
19. Fotherby K., Yong-En S., Howard G., Elder M.G., and Muggeridge J. Return of ovulation and fertility in women using norethisterone oenanthate. Contraception 29 (1984) 447-455
20. Zalanyi S., Landgren B.M., and Johannisson E. Pharmacokinetics, pharmacodynamic and endometrial effects of a single dose of 200 mg norethisterone enanthate. Contraception 30 (1984) 225-237
21. Fotherby K., Hamawi A., Howard G., Bye P.G., and Elder M. Pharmacokinetics of different doses of norethisterone oenanthate. Contraception 29 (1984) 325-333
22. Werawatgoompa S., Vaivanijkul B., Leepipatpaiboon S., Channiyom K., Virutamasen P., and Dusitsin N. The effect of injectable norethisterone oenanthate on ovarian hormones in Thai women. Contraception 21 (1980) 299-309
23. Goebelsmann U., Stanczyk F.Z., Brenner P.F., Goebelsmann A.E., Gentzschein E.K., and Mishell Jr. D.R. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone. Contraception 19 (1979) 283-313
24. Fotherby K., Howard G., Shrimanker K., Elder M., and Bye P.G. Occurrence of ovulation in women receiving the injectable contraceptive norethisterone oenanthate. Contraception 18 (1978) 535-542
25. Schwallie P.C., and Assenzo J.R. The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review. Contraception 10 (1974) 181-202
26. Landgren B.M., and Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 21 (1980) 87-113
27. Dahlberg K. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user. Int J Gynaecol Obstet 20 (1982) 43-48
28. Pardthaisong T., and Gray R.H. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 134 (1991) 795-803
29. Gray R.H., and Pardthaisong T. In utero exposure to steroid contraceptives and survival during infancy. Am J Epidemiol 134 (1991) 804-811
30. Pardthaisong T., Yenchit C., and Gray R. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation. Contraception 45 (1992) 313-324
31. World Health Organization. Selected practice recommendations for contraceptive use, 2008 update (2008), World Health Organization, Geneva. http://www.who.int/reproductive-health/publications/spr/spr_2008_update.pdf Accessed December 1, 2008